CAR-T cell (Yi Zhang)

CAR-T cell (Yi Zhang) refers to a group of investigational chimeric antigen receptor (CAR) T-cell therapies being evaluated by researcher Yi Zhang at the First Affiliated Hospital of Zhengzhou University. These therapies involve the ex vivo genetic modification of a patient's autologous T cells to express receptors that target specific tumor-associated antigens. The clinical program, specifically trial NCT04106076, is an Early Phase 1 study investigating the safety and efficacy of these multi-target CAR-T cells across a broad spectrum of advanced malignancies. The study includes various solid tumors such as non-small cell lung cancer, gastric cancer, and pancreatic cancer, as well as hematological malignancies like lymphoma. Administration is typically via intravenous infusion, though local interventional or injection methods may be utilized depending on the tumor site and patient needs.

Other names

CAR-T cell-Yi Zhang-non-small cell lung cancer-esophageal squamous cell carcinoma-gastric cancer-colorectal cancer-liver cancer-pancreatic cancer-kidney cancer-cervical squamous cell carcinoma-ovarian cancer-breast cancer-melanoma-glioma-lymphomaCAR-T cell reinfusionGenetically Modified T Cells (Yi Zhang)